Connable Office Inc. lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 13.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,252 shares of the company’s stock after selling 3,771 shares during the period. Connable Office Inc.’s holdings in Johnson & Johnson were worth $3,208,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. State Street Corp increased its position in Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares in the last quarter. Harbour Capital Advisors LLC increased its position in Johnson & Johnson by 13,327.8% during the 2nd quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock worth $18,909,000 after purchasing an additional 2,482,843 shares in the last quarter. Canada Pension Plan Investment Board increased its position in Johnson & Johnson by 33.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 4,696,566 shares of the company’s stock worth $621,309,000 after purchasing an additional 1,189,900 shares in the last quarter. Bank of Nova Scotia increased its position in Johnson & Johnson by 94.5% during the 1st quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock worth $145,914,000 after purchasing an additional 569,313 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. acquired a new position in Johnson & Johnson during the 1st quarter worth approximately $65,598,000. 65.61% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.watchlistnews.com/johnson-johnson-jnj-stake-decreased-by-connable-office-inc/1718819.html.

Several equities analysts have issued reports on the stock. J P Morgan Chase & Co upped their price target on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Tuesday, August 15th. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target for the company. in a research report on Monday, September 18th. Stifel Nicolaus upped their price target on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Finally, Citigroup Inc. upped their price target on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and an average price target of $143.70.

Johnson & Johnson (JNJ) opened at $138.34 on Wednesday. The stock has a market cap of $370,551.69, a price-to-earnings ratio of 19.32, a P/E/G ratio of 2.80 and a beta of 0.82. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $144.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. Johnson & Johnson’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.68 earnings per share. analysts predict that Johnson & Johnson will post 7.28 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.43%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.